Last reviewed · How we verify

Crestor — Competitive Intelligence Brief

Crestor (rosuvastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor (statin). Area: Metabolic.

marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Crestor (rosuvastatin) — AstraZeneca. Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Crestor TARGET rosuvastatin AstraZeneca marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 2003-01-01
Lipitor atorvastatin Pfizer Inc. marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 1996-12-17
FLUVASTATIN SODIUM FLUVASTATIN SODIUM marketed HMG-CoA reductase 1993-01-01
Lescol FLUVASTATIN Novartis marketed HMG-CoA Reductase Inhibitor HMG-CoA reductase 1993-01-01
Ezetimibe and Simvastatin Ezetimibe and Simvastatin University of Texas Southwestern Medical Center marketed Combination lipid-lowering agent (ezetimibe + statin) NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Atorvastatin-omeprazole Atorvastatin-omeprazole Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec marketed Fixed-dose combination (statin + proton pump inhibitor) HMG-CoA reductase (atorvastatin); H+/K+-ATPase (omeprazole)
Continue Ritonavir-boosted PI+Rosuvastatin Continue Ritonavir-boosted PI+Rosuvastatin Juan A. Arnaiz marketed Antiretroviral combination (protease inhibitor + statin) HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (HMG-CoA reductase inhibitor (statin) class)

  1. Organon and Co · 7 drugs in this class
  2. Kuhnil Pharmaceutical Co., Ltd. · 3 drugs in this class
  3. Wenzhou Medical University · 2 drugs in this class
  4. Amgen · 2 drugs in this class
  5. Beijing Tiantan Hospital · 2 drugs in this class
  6. Seoul National University Hospital · 2 drugs in this class
  7. JW Pharmaceutical · 2 drugs in this class
  8. AstraZeneca · 2 drugs in this class
  9. Korea University Anam Hospital · 2 drugs in this class
  10. Gachon University Gil Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Crestor — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: